LUCIUS 卢修斯 索托拉西布 Sotorasib非小细胞肺癌

索托拉西布

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Sotorasib

老挝国家食药监局批准上市
老挝国家药检所检测认证

非小细胞肺癌

Composition:
Each LuciSot tablet contains: Sotorasib 120mg
ciSot is for the treatment of adult patients with

LUCIUS

RASG12C-mutated locally advanced or
metastatic non-small cell lung cancer (NSCLC)

PHARMACEUTICALS

The recommended dosage of LuciSot is 960 mg
(eieht 120 me tablets) orally once daily. Take
LociSot at the same time each day with or withou

LUCISOT

food.
Recommended LuciSot Dose Reduction Levels for
Adverse Reactions:
1. First dose reduction: 480 mg (4 tablets ) once daily

FDA批准

2.Second dose reduction: 240mg (2 tablets) once
daily.

SOTORASIB TABLETS

Tablets should be swallowed whole & not chewed
or crushed.

120mg

Storage: in a dry place and store at 20°C to 25°C
Warning
Keep medicine out of the reach of Children. Do not
administered LuciSot in Pregnancy and Lactation
patient treatment.

PLEASE SEEPACKAGE INSERT
Manufactured and Marketed by
LUCIUS

权威认证

Thongmang village, Xaythany district,
Vientiane Capital, Laos
Warning and Precaution: To be sold by reta
on prescription of a Registered oncologist
only, and as directed by the physician.

56 Tablets

口碑质量

适应症:

适用于治疗KRAS G12C突变的局部晚期或转移性
非小细胞肺癌(NSCLC)的成年患者:这些患者之前
至少接受过一次全身治疗。
推荐剂量:
1、每日口服一次,每次960mg;
2 、 整 片 吞 服 , 随 或 不 随 食 物